Glucagon-like peptides 1 and 2 in health and disease: A review

Peptides

Volumn 44, Issue , 2013, Pages 75-86

  Marathe, Chinmay S ^a   Rayner, Christopher K ^a   Jones, Karen L ^a   Horowitz, Michael ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Gastric emptying; Glucagon like peptides; Incretin secretion; Postprandial glycemia

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INCRETIN; LIRAGLUTIDE; MESSENGER RNA; METFORMIN; PREPROGLUCAGON; TEDUGLUTIDE;

ALZHEIMER DISEASE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG HALF LIFE; GASTROINTESTINAL MOTILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; INTESTINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; REVIEW; ROSE; SHORT BOWEL SYNDROME; STOMACH EMPTYING; TACHYPHYLAXIS;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INCRETINS; PANCREAS; POSTPRANDIAL PERIOD; RECEPTORS, GLUCAGON;

EID: 84875985453     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.01.014     Document Type: Review

References (161)

1. C.R. Abbott, M. Monteiro, C.J. Small, A. Sajedi, K.L. Smith, and J.R. Parkinson The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway Brain Res 1044 2005 127 131 (Pubitemid 40616060)
2. B. Ahren The future of incretin-based therapy: novel avenues-novel targets Diabetes Obes Metab 13 Suppl. 1 2011 158 166
3. A. Astrup, S. Rossner, L. Van Gaal, A. Rissanen, L. Niskanen, and M. Al Hakim Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
4. J.I. Bagger, F.K. Knop, A. Lund, H. Vestergaard, J.J. Holst, and T. Vilsboll Impaired regulation of the incretin effect in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 737 745
5. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157 (Pubitemid 46711096)
6. S. Baldassano, A.L. Bellanca, R. Serio, and F. Mule Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2 J Endocrinol 213 2012 277 284
7. W.M. Bayliss, and E.H. Starling The mechanism of pancreatic secretion J Physiol 28 1902 325 353
8. C. Beglinger, B. Poller, E. Arbit, C. Ganzoni, S. Gass, and I. Gomez-Orellana Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects Clin Pharmacol Ther 84 2008 468 474
9. G.I. Bell, R.F. Santerre, and G.T. Mullenbach Hamster preproglucagon contains the sequence of glucagon and two related peptides Nature 302 1983 716 718 (Pubitemid 13120276)
10. R. Bergenstal, A. Lewin, T. Bailey, D. Chang, T. Gylvin, and V. Roberts Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea Curr Med Res Opin 25 2009 65 75
11. E. Blase, K. Taylor, H.Y. Gao, M. Wintle, and M. Fineman Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects J Clin Pharmacol 45 2005 570 577 (Pubitemid 40562948)
12. S. Bor, G. Kitapcioglu, P. Dettmar, and T. Baxter Association of heartburn during pregnancy with the risk of gastroesophageal reflux disease Clin Gastroenterol Hepatol 5 2007 1035 1039
13. A. Bozkurt, E. Naslund, J.J. Holst, and P.M. Hellstrom GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat Regul Pept 107 2002 129 135 (Pubitemid 34876454)
14. W. Brener, T.R. Hendrix, and P.R. McHugh Regulation of the gastric emptying of glucose Gastroenterology 85 1983 76 82 (Pubitemid 13106327)
15. J.C. Brown, V. Mutt, and R.A. Pederson Further purification of a polypeptide demonstrating enterogastrone activity J Physiol 209 1970 57 64
16. P.L. Brubaker, and D.J. Drucker Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659 (Pubitemid 38686211)
17. P.L. Brubaker, D.J. Drucker, S.L. Asa, C. Swallow, M. Redston, and G.R. Greenberg Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor J Clin Endocrinol Metab 87 2002 3078 3083 (Pubitemid 34816348)
18. A.L. Buchman, S. Katz, J.C. Fang, C.N. Bernstein, and S.G. Abou-Assi Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease Inflamm Bowel Dis 16 2010 962 973
19. M.C. Bunck, A. Corner, B. Eliasson, R.J. Heine, R.M. Shaginian, and M.R. Taskinen Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes Diabetes Care 34 2011 2041 2047
20. M.C. Bunck, M. Diamant, A. Corner, B. Eliasson, J.L. Malloy, and R.M. Shaginian One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial Diabetes Care 32 2009 762 768
21. J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis, and A.Y. Kwan Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 154 2011 103 112
22. J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, and H. Hu DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 2010 1255 1261
23. J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, and J.H. Brett Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
24. P.J. Collins, M. Horowitz, D.J. Cook, P.E. Harding, and D.J. Shearman Gastric emptying in normal subjects-a reproducible technique using a single scintillation camera and computer system Gut 24 1983 1117 1125 (Pubitemid 14205812)
25. W. Creutzfeldt The incretin concept today Diabetologia 16 1979 75 85 (Pubitemid 9231263)
26. W. Creutzfeldt The [pre-] history of the incretin concept Regul Pept 128 2005 87 91 (Pubitemid 40380908)
27. M.H. Davidson Cardiovascular effects of glucagonlike peptide-1 agonists Am J Cardiol 108 2011 33B 41B
28. C.F. Deacon Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes Metab 13 2011 7 18
29. C.F. Deacon, L. Pridal, L. Klarskov, M. Olesen, and J.J. Holst Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig Am J Physiol 271 1996 E458 E464
30. A.M. Deane, N.Q. Nguyen, J.E. Stevens, R.J. Fraser, R.H. Holloway, and L.K. Besanko Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia J Clin Endocrinol Metab 95 2010 215 221
31. D. Donnelly The structure and function of the glucagon-like peptide-1 receptor and its ligands Br J Pharmacol 166 1 2012 27 41 10.1111/j.1476-5381. 2011.01687.x
32. D.J. Drucker, and S. Asa Glucagon gene expression in vertebrate brain J Biol Chem 263 1988 13475 13478
33. D.J. Drucker, and P.L. Brubaker Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine Proc Natl Acad Sci USA 86 1989 3953 3957 (Pubitemid 19154723)
34. D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, and D. Zhuang Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
35. D.J. Drucker, P. Erlich, S.L. Asa, and P.L. Brubaker Induction of intestinal epithelial proliferation by glucagon-like peptide 2 Proc Natl Acad Sci USA 93 1996 7911 7916 (Pubitemid 26277138)
36. D.J. Drucker, S.I. Sherman, R.M. Bergenstal, and J.B. Buse The safety of incretin-based therapies-review of the scientific evidence J Clin Endocrinol Metab 96 2011 2027 2031
37. J. Dupre, S.A. Ross, D. Watson, and J.C. Brown Stimulation of insulin secretion by gastric inhibitory polypeptide in man J Clin Endocrinol Metab 37 1973 826 828
38. R. Ebert, H. Unger, and W. Creutzfeldt Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption Diabetologia 24 1983 449 454 (Pubitemid 13057382)
39. B. Moore, E.S. Edie, and J.H. Abram On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane Biochem J 1 1906 28 38
40. C.M. Edwards, J.F. Todd, M. Mahmoudi, Z. Wang, R.M. Wang, and M.A. Ghatei Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 Diabetes 48 1999 86 93 (Pubitemid 29019356)
41. S. Efrat, G. Teitelman, M. Anwar, D. Ruggiero, and D. Hanahan Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells Neuron 1 1988 605 613
42. H. Elrick, L. Stimmler, C.J. Hlad Jr., and Y. Arai Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 24 1964 1076 1082
43. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515 520 (Pubitemid 28084232)
44. M. Giralt, and P. Vergara Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat Dig Dis Sci 44 1999 322 329 (Pubitemid 29093556)
45. M.A. Gulpinar, A. Bozkurt, T. Coskun, N.B. Ulusoy, and B.C. Yegen Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats Am J Physiol Gastrointest Liver Physiol 278 2000 G924 G929
46. M.K. Gutniak, B. Linde, J.J. Holst, and S. Efendic Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM Diabetes Care 17 1994 1039 1044 (Pubitemid 24268617)
47. L. Hansen, C.F. Deacon, C. Orskov, and J.J. Holst Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 140 1999 5356 5363
48. K.J. Hare, F.K. Knop, M. Asmar, S. Madsbad, C.F. Deacon, and J.J. Holst Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus J Clin Endocrinol Metab 94 2009 4679 4687
49. B. Hartmann, M.B. Harr, P.B. Jeppesen, M. Wojdemann, C.F. Deacon, and P.B. Mortensen In vivo and in vitro degradation of glucagon-like peptide-2 in humans J Clin Endocrinol Metab 85 2000 2884 2888 (Pubitemid 32269168)
50. P.M. Hellstrom, J. Hein, P. Bytzer, E. Bjornsson, J. Kristensen, and H. Schambye Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study Aliment Pharmacol Ther 29 2009 198 206
51. P.M. Hellstrom, E. Naslund, T. Edholm, P.T. Schmidt, J. Kristensen, and E. Theodorsson GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome Neurogastroenterol Motil 20 2008 649 659 (Pubitemid 351678618)
52. J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439 (Pubitemid 350041474)
53. J.J. Holst Glucagon and glucagon-like peptides 1 and 2 Results Probl Cell Differ 50 2010 121 135
54. J.J. Holst, R. Burcelin, and E. Nathanson Neuroprotective properties of GLP-1: theoretical and practical applications Curr Med Res Opin 27 2011 547 558
55. J.J. Holst, M. Christensen, A. Lund, J. de Heer, B. Svendsen, and U. Kielgast Regulation of glucagon secretion by incretins Diabetes Obes Metab 13 Suppl. 1 2011 89 94
56. G.Gt. Holz, W.M. Kuhtreiber, and J.F. Habener Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) Nature 361 1993 362 365 (Pubitemid 23041630)
57. P.J. Hornby, and B.A. Moore The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease Expert Opin Ther Targets 15 2011 637 646
58. M. Horowitz, and J. Dent Disordered gastric emptying: mechanical basis, assessment and treatment Baillieres Clin Gastroenterol 5 1991 371 407
59. E.C. Hoyt, P.K. Lund, D.E. Winesett, C.R. Fuller, M.A. Ghatei, and S.R. Bloom Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum Diabetes 45 1996 434 439 (Pubitemid 26110248)
60. K. Hupe-Sodmann, G.P. McGregor, R. Bridenbaugh, R. Goke, B. Goke, and H. Thole Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides Regul Pept 58 1995 149 156
61. A. Hvidberg, M.T. Nielsen, J. Hilsted, C. Orskov, and J.J. Holst Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man Metabolism 43 1994 104 108 (Pubitemid 24047112)
62. D.M. Irwin, O. Huner, and J.H. Youson Lamprey proglucagon and the origin of glucagon-like peptides Mol Biol Evol 16 1999 1548 1557 (Pubitemid 29510898)
63. J. Jelsing, N. Vrang, G. Hansen, K. Raun, M. Tang-Christensen, and L. Bjerre Knudsen Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight Diabetes Obes Metab 14 2012 531 538
64. I.R. Jones, D.R. Owens, S. Luzio, S. Williams, and T.M. Hayes The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 32 1989 668 677 (Pubitemid 19235993)
65. K.L. Jones, A. Russo, M.K. Berry, J.E. Stevens, J.M. Wishart, and M. Horowitz A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus Am J Med 113 2002 449 455 (Pubitemid 35335795)
66. U. Kielgast, M. Asmar, S. Madsbad, and J.J. Holst Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients J Clin Endocrinol Metab 95 2010 2492 2496
67. F.K. Knop, K.J. Hare, J. Pedersen, J.W. Hendel, J.J. Holst, and S.S. Poulsen Prohormone convertase 2 positive enteroendocrine cells are more abundant in patients with type 2 diabetes: a potential source of gut-derived glucagon? Diabetologia 54 2011 S1 S543 (Abstract)
68. J. Koska, E.A. Schwartz, M.P. Mullin, D.C. Schwenke, and P.D. Reaven Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes Diabetes Care 33 2010 1028 1030
69. B. Kreymann, G. Williams, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304 (Pubitemid 17156636)
70. J. La Barre Sur les possibilités d'un traitement du diabète par l'incrétine Bull Acad R Med Belg 12 1932 620 634
71. Y.C. Lee, S.L. Asa, and D.J. Drucker Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice J Biol Chem 267 1992 10705 10708
72. P.J. Lefebvre Glucagon and its family revisited Diabetes Care 18 1995 715 730
73. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J Biol Chem 278 2003 471 478 (Pubitemid 36043598)
74. H. Linnebjerg, S. Park, P.A. Kothare, M.E. Trautmann, K. Mace, and M. Fineman Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regul Pept 151 2008 123 129
75. T.J. Little, S. Doran, J.H. Meyer, A.J. Smout, D.G. O'Donovan, and K.L. Wu The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed Am J Physiol Endocrinol Metab 291 2006 E647 E655
76. E.R. Loew, J.S. Gray, and A.C. Ivy The effect of duodenal instillation of hydrochloric acid upon the fasting blood sugar of dogs Am J Physiol 126 1939 270 276
77. E.R. Loew, J.S. Gray, and A.C. Ivy The effect of acid stimulation of the duodenum upon experimental hyperglycemia and utilization of glucose Am J Physiol 128 1940 298 308
78. E.R. Loew, J.S. Gray, and A.C. Ivy Is a duodenal hormone involved in carbohydrate metabolism Am J Physiol 129 1940 659 663
79. Z. Lojda Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase). II. Blood vessels Histochemistry 59 1979 153 166 (Pubitemid 9088411)
80. M. Lorenz, C. Pfeiffer, A. Steinstraber, and P. Ruus Effects of lixisenatide once daily on gastric emptying and relationships to postprandial glycemia in type 2 diabetes mellitus Diabetes June 2012 Abstract
81. A. Lund, T. Vilsboll, J.I. Bagger, J.J. Holst, and F.K. Knop The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes Am J Physiol Endocrinol Metab 300 2011 E1038 E1046
82. P.K. Lund, R.H. Goodman, P.C. Dee, and J.F. Habener Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem Proc Natl Acad Sci USA 79 1982 345 349 (Pubitemid 12137713)
83. J. Ma, A.N. Pilichiewicz, C. Feinle-Bisset, J.M. Wishart, K.L. Jones, and M. Horowitz Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes Diabet Med 29 2012 604 608
84. J. Ma, J.E. Stevens, K. Cukier, A.F. Maddox, J.M. Wishart, and K.L. Jones Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes Diabetes Care 32 2009 1600 1602
85. C.S. Marathe, C.K. Rayner, K.L. Jones, and M. Horowitz Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function Exp Diabetes Res 2011 2011 279530
86. H.E. Mardini, and W.J. de Villiers Teduglutide in intestinal adaptation and repair: light at the end of the tunnel Expert Opin Investig Drugs 17 2008 945 951 (Pubitemid 351864331)
87. N. McIntyre, C.D. Holdsworth, and D.S. Turner New interpretation of oral glucose tolerance Lancet 41 1964 20 21
88. J.J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J.J. Holst, and W.E. Schmidt Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes J Clin Endocrinol Metab 88 2003 2719 2725 (Pubitemid 36733545)
89. J.J. Meier, B. Gallwitz, N. Siepmann, J.J. Holst, C.F. Deacon, and W.E. Schmidt Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia Diabetologia 46 2003 798 801 (Pubitemid 36831408)
90. J.J. Meier, G. Kemmeries, J.J. Holst, and M.A. Nauck Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects Diabetes 54 2005 2212 2218 (Pubitemid 40911286)
91. J.J. Meier, L.L. Kjems, J.D. Veldhuis, P. Lefebvre, and P.C. Butler Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis Diabetes 55 2006 1051 1056 (Pubitemid 44100181)
92. J.J. Meier, and M.A. Nauck Glucagon-like peptide 1(GLP-1) in biology and pathology Diabetes Metab Res Rev 21 2005 91 117 (Pubitemid 40467658)
93. J.J. Meier, M.A. Nauck, A. Pott, K. Heinze, O. Goetze, and K. Bulut Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans Gastroenterology 130 2006 44 54 (Pubitemid 43049834)
94. G.S. Meneilly, N. Greig, H. Tildesley, J.F. Habener, J.M. Egan, and D. Elahi Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes Diabetes Care 26 2003 2835 2841 (Pubitemid 37205555)
95. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 214 1993 829 835 (Pubitemid 23188160)
96. S. Mojsov, G. Heinrich, I.B. Wilson, M. Ravazzola, L. Orci, and J.F. Habener Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing J Biol Chem 261 1986 11880 11889 (Pubitemid 17206117)
97. L. Monnier, H. Lapinski, and C. Colette Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 26 2003 881 885 (Pubitemid 36929359)
98. D.G. Munroe, A.K. Gupta, F. Kooshesh, T.B. Vyas, G. Rizkalla, and H. Wang Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2 Proc Natl Acad Sci USA 96 1999 1569 1573 (Pubitemid 29098492)
99. S. Myojo, T. Tsujikawa, M. Sasaki, Y. Fujiyama, and T. Bamba Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro J Gastroenterol 32 1997 300 305 (Pubitemid 27254795)
100. E. Naslund, B. Barkeling, N. King, M. Gutniak, J.E. Blundell, and J.J. Holst Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int J Obes Relat Metab Disord 23 1999 304 311 (Pubitemid 29118862)
101. M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1986 46 52 (Pubitemid 16162741)
102. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 124 2011 S3 S18
103. M.A. Nauck, S. Duran, D. Kim, D. Johns, J. Northrup, and A. Festa A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Diabetologia 50 2007 259 267
104. M.A. Nauck, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert, and W. Creutzfeldt Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 91 1993 301 307 (Pubitemid 23037285)
105. M.A. Nauck, E. Homberger, E.G. Siegel, R.C. Allen, R.P. Eaton, and R. Ebert Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 1986 492 498 (Pubitemid 16035703)
106. M.A. Nauck, G. Kemmeries, J.J. Holst, and J.J. Meier Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans Diabetes 60 2011 1561 1565
107. M.A. Nauck, U. Niedereichholz, R. Ettler, J.J. Holst, C. Orskov, and R. Ritzel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 273 1997 E981 E988
108. M.A. Nauck, I. Vardarli, C.F. Deacon, J.J. Holst, and J.J. Meier Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down Diabetologia 54 2011 10 18
109. M.A. Nauck, D. Wollschlager, J. Werner, J.J. Holst, C. Orskov, and W. Creutzfeldt Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM Diabetologia 39 1996 1546 1553 (Pubitemid 26397366)
110. M. Nian, D.J. Drucker, and D. Irwin Divergent regulation of human and rat proglucagon gene promoters in vivo Am J Physiol 277 1999 G829 G837
111. M. Nicolaus, J. Brodl, R. Linke, H.J. Woerle, B. Goke, and J. Schirra Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying J Clin Endocrinol Metab 96 2011 229 236
112. B. Nuche-Berenguer, P. Moreno, P. Esbrit, S. Dapia, J.R. Caeiro, and J. Cancelas Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states Calcif Tissue Int 84 2009 453 461
113. B. Nuche-Berenguer, P. Moreno, S. Portal-Nunez, S. Dapia, P. Esbrit, and M.L. Villanueva-Penacarrillo Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states Regul Pept 159 2010 61 66
114. C. Orskov, A. Wettergren, and J.J. Holst Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable Diabetes 42 1993 658 661 (Pubitemid 23127154)
115. N.B. Pedersen, K.R. Hjollund, A.H. Johnsen, C. Orskov, M.M. Rosenkilde, and B. Hartmann Porcine glucagon-like peptide-2: structure, signaling, metabolism and effects Regul Pept 146 2008 310 320
116. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, and J.M. Egan Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J Neurosci Res 72 2003 603 612 (Pubitemid 36578646)
117. A.N. Pilichiewicz, R. Chaikomin, I.M. Brennan, J.M. Wishart, C.K. Rayner, and K.L. Jones Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men Am J Physiol Endocrinol Metab 293 2007 E743 E753
118. A. Plamboeck, J.J. Holst, R.D. Carr, and C.F. Deacon Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig Diabetologia 48 2005 1882 1890 (Pubitemid 41317844)
119. J.N. Roberge, and P.L. Brubaker Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients Endocrinology 128 1991 3169 3174
120. J.N. Roberge, and P.L. Brubaker Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop Endocrinology 133 1993 233 240 (Pubitemid 23206398)
121. A.S. Rocca, and P.L. Brubaker Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion Endocrinology 140 1999 1687 1694 (Pubitemid 29149238)
122. S.A. Ross, J.C. Brown, and J. Dupre Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus Diabetes 26 1977 525 529 (Pubitemid 8124531)
123. Y. Rouille, S. Martin, and D.F. Steiner Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide J Biol Chem 270 1995 26488 26496
124. Y. Rouille, G. Westermark, S.K. Martin, and D.F. Steiner Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells Proc Natl Acad Sci USA 91 1994 3242 3246 (Pubitemid 24130212)
125. K.J. Rowland, and P.L. Brubaker Life in the crypt: a role for glucagon-like peptide-2 Mol Cell Endocrinol 288 2008 63 70
126. K.J. Rowland, and P.L. Brubaker The "cryptic" mechanism of action of glucagon-like peptide-2 Am J Physiol Gastrointest Liver Physiol 301 2011 G1 G8
127. M. Salehi, T.P. Vahl, and D.A. D'Alessio Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion J Clin Endocrinol Metab 93 2008 4909 4916
128. M. Sander, A. Neubuser, J. Kalamaras, H.C. Ee, G.R. Martin, and M.S. German Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development Genes Dev 11 1997 1662 1673 (Pubitemid 27300592)
129. R.R. Schick, J.P. Zimmermann, T. vorm Walde, and V. Schusdziarra Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats Am J Physiol Regul Integr Comp Physiol 284 2003 R1427 R1435
130. P.T. Schmidt, E. Naslund, P. Gryback, H. Jacobsson, B. Hartmann, and J.J. Holst Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety Regul Pept 116 2003 21 25 (Pubitemid 37352911)
131. W.E. Schmidt, E.G. Siegel, and W. Creutzfeldt Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets Diabetologia 28 1985 704 707 (Pubitemid 16226411)
132. W.T. Schroeder, L.C. Lopez, M.E. Harper, and G.F. Saunders Localization of the human glucagon gene (GCG) to chromosome segment 2q36-37 Cytogenet Cell Genet 38 1984 76 79 (Pubitemid 14127739)
133. M.W. Schwartz, S.C. Woods, D. Porte Jr., R.J. Seeley, and D.G. Baskin Central nervous system control of food intake Nature 404 2000 661 671 (Pubitemid 30205071)
134. D.S. Shyangdan, P.L. Royle, C. Clar, P. Sharma, and N.R. Waugh Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis BMC Endocr Disord 10 2010 20
135. D.L. Sigalet Nonruminant nutrition symposium: the role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander J Anim Sci 90 2012 1224 1232
136. G.L. Sowden, D.J. Drucker, D. Weinshenker, and S.J. Swoap Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor Am J Physiol Regul Integr Comp Physiol 292 2007 R962 R970
137. R.E. Steinert, B. Poller, M.C. Castelli, J. Drewe, and C. Beglinger Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects Am J Clin Nutr 92 2010 810 817
138. J.E. Stevens, M. Horowitz, C.F. Deacon, M. Nauck, C.K. Rayner, and K.L. Jones The effects of sitagliptin on gastric emptying in healthy humans-a randomised, controlled study Aliment Pharmacol Ther 36 4 2012 379 390 10.1111/j.1365-2036.2012.05198.x [Epub 2012 Jun 28]
139. S. Teramoto, N. Miyamoto, K. Yatomi, Y. Tanaka, H. Oishi, and H. Arai Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia J Cereb Blood Flow Metab 31 2011 1696 1705
140. M.J. Theodorakis, O. Carlson, S. Michopoulos, M.E. Doyle, M. Juhaszova, and K. Petraki Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP Am J Physiol Endocrinol Metab. 290 2006 E550 E559
141. B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proc Natl Acad Sci USA 89 1992 8641 8645
142. J.F. Todd, C.M. Edwards, M.A. Ghatei, H.M. Mather, and S.R. Bloom Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes Clin Sci (Lond) 95 1998 325 329 (Pubitemid 28444841)
143. M.B. Toft-Nielsen, S. Madsbad, and J.J. Holst Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients Diabetes Care 22 1999 1137 1143 (Pubitemid 29293967)
144. M.B. Toft-Nielsen, S. Madsbad, and J.J. Holst Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes J Clin Endocrinol Metab 86 2001 3853 3860 (Pubitemid 32755988)
145. S.S. Torekov, S. Madsbad, and J.J. Holst Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential Obes Rev 12 2011 593 601
146. D.K. Trinh, K. Zhang, M. Hossain, P.L. Brubaker, and D.J. Drucker Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium Diabetes 52 2003 425 433 (Pubitemid 36173199)
147. C.H. Tsai, M. Hill, S.L. Asa, P.L. Brubaker, and D.J. Drucker Intestinal growth-promoting properties of glucagon-like peptide-2 in mice Am J Physiol 273 1997 E77 E84
148. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012 (Pubitemid 29254858)
149. M.D. Turton, D. O'Shea, I. Gunn, S.A. Beak, C.M. Edwards, and K. Meeran A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 1996 69 72 (Pubitemid 26008136)
150. K. Vollmer, J.J. Holst, B. Baller, M. Ellrichmann, M.A. Nauck, and W.E. Schmidt Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance Diabetes 57 2008 678 687
151. X. Wang, C.M. Cahill, M.A. Pineyro, J. Zhou, M.E. Doyle, and J.M. Egan Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells Endocrinology 140 1999 4904 4907 (Pubitemid 30666159)
152. J.W. White, and G.F. Saunders Structure of the human glucagon gene Nucleic Acids Res 14 1986 4719 4730 (Pubitemid 16088660)
153. D.L. Williams, D.G. Baskin, and M.W. Schwartz Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety Endocrinology 150 2009 1680 1687
154. J.M. Wishart, M. Horowitz, H.A. Morris, K.L. Jones, and M.A. Nauck Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1 Peptides 19 1998 1049 1053 (Pubitemid 28383802)
155. A.B. Witte, P. Gryback, H. Jacobsson, E. Naslund, P.M. Hellstrom, and
156. T. Wu, C.K. Rayner, K. Jones, and M. Horowitz Dietary effects on incretin hormone secretion Vitam Horm 84 2010 81 110
157. T. Wu, B.R. Zhao, M.J. Bound, H.L. Checklin, M. Bellon, and T.J. Little Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans Am J Clin Nutr 95 2012 78 83
158. Q. Xiao, R.P. Boushey, D.J. Drucker, and P.L. Brubaker Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans Gastroenterology 117 1999 99 105 (Pubitemid 29297625)
159. B. Yusta, L. Huang, D. Munroe, G. Wolff, R. Fantaske, and S. Sharma Enteroendocrine localization of GLP-2 receptor expression in humans and rodents Gastroenterology 119 2000 744 755
160. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830 (Pubitemid 34233752)
161. L. Zhou, M. Nian, and J. Gu Irwin DM. Intron 1 sequences are required for pancreatic expression of the human proglucagon gene Am J Physiol Regul Integr Comp Physiol 290 2006 R634 R641